CSL has announced the sale of its Wuhan Zhong Yuan Rui De Biologicals Products plasma collection and fractionation operations to Chengdu Rongsheng Pharmaceutical for USD$185 million in cash proceeds. …
CSL announces sale of Wuhan plasma collection and fractionation operations
September 5, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 28, 2025 - - Australian Biotech -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 - - Australian Biotech -
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 - - Latest News -
Repurposed diabetes drug could deliver gains for people living with major joint pain
April 27, 2025 - - Latest News